Skip to main content
. Author manuscript; available in PMC: 2019 Nov 12.
Published in final edited form as: Bioconjug Chem. 2017 Nov 30;29(3):813–823. doi: 10.1021/acs.bioconjchem.7b00624

Figure 1.

Figure 1.

Surface-coupled TGF-β is bioactively delivered by PLG nanoparticles. (A) Schematic depiction of the NP production and TGF-β conjugation procedure used to create the NPs in this study. TGF-β was conjugated to blank PLG, Ag-encapsulated, and Ag-polymer conjugate NPs. (B) Naïve CD4+CD25− T cells were cultured in anti-CD3-coated plates for 4 days in the presence of 2 μg/mL anti-CD28, 10 ng/mL IL-2, and 2 ng/mL of soluble TGF-β, blank PLG NPs, or 300 μg/mL of PLG-TGF-β NPs (166 ng TGF-β/mg). T cells were characterized by flow cytometry for CD25 and intracellular Foxp3.